TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Must have X-ray confirmed successful hip fracture repair; Must have completed surgical wound healing; Ability to walk a specified distance with or without a walking aid; Must weigh at least 35 kg.~Exclusion Criteria:~Must not have history of any other lower limb fractures in the past 6 months; Must not have certain cardiovascular conditions; Must not have a chronic active infection (e.g. HIV, hepatitis B or C, etc); Must not have used high-dose corticosteroid medications for at least 3 months in the past year;

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bimagrumab 700 mg (Type: EXPERIMENTAL): Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
- bimagrumab 210 mg (Type: EXPERIMENTAL): Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
- placebo (Type: PLACEBO_COMPARATOR): Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
- Bimagrumab 70 mg (Type: EXPERIMENTAL): Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 %~* Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5%~* Body mass index (BMI) 18.5-40 kg/m\^2~* Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator)~Exclusion Criteria:~* Impaired liver function~* Impaired renal function~* Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure~* Any clinically significant abnormal ECG (electrocardiogram)~* Uncontrolled treated/untreated hypertension~* Recurrent severe hypoglycaemia as judged by the Investigator~* Active hepatitis B and/or active hepatitis C~* Positive human immunodeficiency virus (HIV) antibodies~* Known or suspected allergy to trial product(s) or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed stage IV or recurrent NSCLC~* Measurable disease by RECIST 1.0~* Must have received at least one prior line of therapy for advanced lung cancer (no maximum number)~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Pregnant or breastfeeding~* Radiation within 2 weeks~* Cytotoxic chemotherapy or monoclonal antibodies within 4 weeks~* EGFR tyrosine kinase inhibitor within 2 weeks~* Other small molecule inhibitor within 2 weeks~* Experimental treatment within 30 days~* Prior treatment with any HSP90 or HDAC inhibitor compound~* Known and untreated brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922~* Unresolved diarrhea greater than or equal to CTCAE version 4, grade 1~* Major surgery within 2 weeks of starting study drug or have not recovered from side effects of surgery~* Known disorders due to a deficiency in bilirubin glucuronidation~* Requiring use of therapeutic doses of warfarin (Coumadin)~* History of long QT syndrome~* History of clinically manifest ischemic heart disease, heart failure or left ventricular dysfunction~* Clinically significant ECG abnormalities~* Other clinically significant heart disease~* Currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes~* On a cardiac pacemaker~* Concurrent malignancies or invasive cancers diagnosed within 3 years except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix~* Known to be HIV positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUY922 Treatment Arm (Type: EXPERIMENTAL): AUY922 administered once weekly via intravenous, 70 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polestriding Versus Walking for Subjects With Poor Leg Circulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral Vascular Disease~* Cramping/Claudication Pain in legs while walking~* Ankle Brachial Index (measure of circulation by doppler) .90 or less~Exclusion Criteria:~* Ulcers or sores on feet or legs~* Unable to walk or confined to a wheelchair~* Amputations or severe arthritis pain in shoulders, knees, or hips~* Medical conditions which would exclude subject from participating in an exercise program~* Vascular Surgery within the last six months, or planning vascular surgery

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Walking with Poles (Type: EXPERIMENTAL): Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
- Traditional walking program (Type: ACTIVE_COMPARATOR): Patients were assigned to a 24 week traditional walking program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Eligible patients had pathological diagnosis of HCC by either surgical resection tissue or core needle biopsy; and had advanced stage of disease that is refractory to or is with unacceptable toxicity of sorafenib. Other eligibility criteria included: Child-Pugh A or B7 classification; Eastern Cooperative Oncology Group-performance status score 0-2; adequate bone marrow (leukocyte count \>3.0 ×109/L, hemoglobin \>8.0 g/L, and platelet count \>60 ×109/L), liver (alanine aminotransferase and aspartate aminotransferase \<200 IU/mL), renal (creatinine \<1.5 times the upper limit of the normal range) and coagulation (international normalized ratio \<2.3) function.~Exclusion Criteria:~* Exclusion criteria included a history of treatment with immune checkpoint inhibitors, allergies to immunetherapeutics, systemic immunosuppressive therapy, and ongoing or active infection, or an active autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study arm (Type: EXPERIMENTAL): Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely.~Others with complete or partial responses would keep on going with mono-ICIs therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed IBS diagnosis per Rome II for diagnosis of IBS.~* Colonoscopy within 2 years as part of IBS diagnostic evaluation.~* Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.~Exclusion Criteria:~* Symptoms of constipation.~* History of other gastrointestinal diseases.~* Type 1 or 2 diabetes.~* Lactose intolerance not controlled by lactose-free diet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
- Rifaximin (Type: EXPERIMENTAL): Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal~* Greater than or equal to 45 years of age~* Osteopenia (lumbar spine bone mineral density \[BMD\] T-score between -1.0 and -2.5, and BMD T-score \> -2.5 at the femoral neck)~Exclusion Criteria:~* Patients with more than one Grade 1 vertebral fracture (as per Genant method; patients with one Grade 1 vertebral fracture are eligible to participate)~* Patients with any Grade 2 or 3 vertebral fracture (as per Genant method)~* Patients with 25-(OH) vitamin D levels less than 15 ng/mL prior to randomization~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid 2x5 mg (Type: EXPERIMENTAL): Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
- Zoledronic Acid 1x5 mg (Type: EXPERIMENTAL): Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given at randomization and Month 12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed or histologically proven stage II-IV renal cell carcinoma~* Completed staging evaluation with computed tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis ≤90 days prior to study enrollment~Exclusion Criteria:~* History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma or basal cell carcinoma of the skin)~* Administered a radioisotope within 5 physical half-lives prior to study enrollment~* Pregnancy ((as determined in accordance with the policies of the positron emission tomography (PET) center))~* Intention to enroll in a blinded therapeutic clinical trial following Positron emission tomography-computed tomography (PET/CT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- 18F-DCFPyL PET/CT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paracervical Block During Office Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women eligible and scheduled for office hysteroscopic placement of essure devices~Exclusion Criteria:~* Planned secondary procedures~* Lidocaine allergy~* Repeat procedures

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine paracervical block (Type: EXPERIMENTAL): 5cc 1% lidocaine injection in each paracervical region
- Saline placebo injection (Type: PLACEBO_COMPARATOR): 5cc Normal Saline injection in each paracervical region

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vaccinated Cohort (Type: None): Participants vaccinated with at least one dose of ZOSTAVAX™
- Unvaccinated Comparison Cohort (Type: None): Participants who are not yet vaccinated with any zoster vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for the Treatment of Dysthymia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria::~* Sign an informed consent form~* 18 years of age or older~* Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception~* Meet DSM-IV criteria for dysthymia~* A screening IDS-C score of 17 or greater~* No history of serious or unstable medical disorder~* Not taking any significant concurrent medications~* Not currently receiving psychotherapy Exclusion Criteria:- Suffering from DSM-IV defined~* delirium, dementia, amnestic, or other cognitive disorders~* mental disorders due to a general medical condition~* factitious or somatoform disorders~* mental retardation or developmental disabilities~* substance or alcohol abuse within the last 3 months~* depressive disorders with current suicidal risk~* psychotic disorders including delusional disorder, somatic type~* dissociative disorder~* personality disorders sufficiently severe to interfere with study participation~* History of DSM-IV defined bipolar I or II disorder~* History of non-response of dysthymia to adequate antidepressant medication~* History of major depression refractory to two adequate trials of antidepressants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zero Sodium Peritoneal Dialysate Protocol Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients actively undergoing peritoneal dialysis (PD) with a functioning PD catheter~2. PD vintage \< 3 years~3. As judged by treating nephrologist to be at or above optimal volume status (i.e., not dehydrated)~Exclusion Criteria:~1. Uncontrolled diabetes with frequent episodes of severe hyperglycemia~2. Systolic blood pressure \< 100 mmHg~3. Serum sodium \< 130 mEq/L~4. 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter~5. Anemia with hemoglobin \<8 g/dL~6. Serum bicarbinate \< 18 mEq/L~7. Anuric renal failure~8. Inability to give written informed consent or follow study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10% dextrose in sterile water (Type: EXPERIMENTAL): Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
- Dianeal Low-Calcium with 4.25% Dextrose (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effectiveness and Safety of MRZF111 in the Treatment of Décolleté Wrinkles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female between ≥18 and ≤65 years old.~* Décolleté wrinkles with a rating of moderate to severe (grade 2 to 3) on the MAS Décolleté Wrinkles-At Rest as determined by the blinded live rater and confirmed by the treating investigator afterwards.~Exclusion Criteria:~* Any previous treatment with fat injections, poly L-lactic acid or permanent dermal fillers (e.g., silicone, polymethyl methacrylate) in the décolleté.~* Any previous surgery, including plastic surgery, or surgical permanent implant in the décolleté or in the breasts that could interfere with effectiveness and safety.~* Any previous thread lifting in the décolleté.~* Previous treatment with collagen fillers, calcium hydroxylapatite (CaHa), and/or long-lasting hyaluronic acid (HA) fillers (e.g., Belotero® Intense/Volume, Juvéderm® Volift/Volbella) in the décolleté within the past 24 months before baseline.~* Previous treatment with other HA fillers in the décolleté within the past 12 months before baseline.~* Previous treatment with botulinum toxin, ablative or fractional laser, microdermabrasion, microneedling, chemical peels and/or non-invasive skin tightening (e.g., ultrasound, radiofrequency, intense pulsed light treatment) in the décolleté within the past 6 months before baseline.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 3 MRZF111 injection cycles (Type: EXPERIMENTAL): Enrolled subjects will receive 3 injection cycles in total at time points Day 1, Week 8, and Week 16.
- 2 MRZF111 injection cycles (Type: EXPERIMENTAL): Enrolled subjects will receive 2 injection cycles in total at time points Day 1, and Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sensorineural hearing loss.~* Mild or greater degree.~* Adult onset.~* Gradual onset.~* Hearing loss stable over past 12 months.~* Etiology of presbyacusis or noise-induced hearing loss.~* Unaided word recognition score between 28% and 86%.~* English as primary spoken language.~* Willing and able to abstain from other treatments or medications to improve hearing ability.~* Willing and able to abstain from work or other activities that involve loud noise exposure.~Exclusion Criteria:~* Central auditory processing disorder.~* Active/recurrent middle ear infection.~* Meniere's disease.~* Tympanic membrane perforation/tubes.~* Cochlear implant.~* Removal of acoustic neuroma.~* Hyperacusis/misphonia.~* Photosensitivity disorder.~* Active infection/wound in head/ear region.~* Pregnant/lactating.~* Serious mental health illness.~* Significant developmental disability/cognitive impairment.~* History of drug/alcohol abuse.~* Involvement in litigation/worker's compensation/disability benefits for hearing loss.~* Other research participation in past 90 days.~* Use of ototoxic medications known to cause temporary or permanent hearing loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- The Hearing Laser (Type: ACTIVE_COMPARATOR): Active low level laser light therapy of 635 nanometers (nm)
- Placebo Laser (Type: PLACEBO_COMPARATOR): inactive low level laser light therapy with no therapeutic output

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete